Gout Medication Febuxostat NAN

(MENAFN- RCTT) The manufacturing enterprise "Akademfarm" offers consumers the drug "Febuxostat NAN", containing the active ingredient febuxostat and used to treat gout, under a manufacturing agreement and is looking for partners to conclude a distribution services agreement. Description Febuxostat-based medications (a potent, non-purine, selective xanthine oxidase inhibitor) are used to treat chronic hyperuricemia associated with gout. They effectively reduce blood uric acid levels by blocking the enzyme responsible for its synthesis. This prevents new attacks of gouty arthritis and promotes the gradual resolution of tophi.
World leaders and original brands.
1. Teijin Pharma Limited (Japan)
Product Features: The developer of the original febuxostat molecule (brand name Feburic). The company's products exhibit benchmark bioavailability. This serves as the quality standard ("gold standard") by which all global generic drug manufacturers conduct bioequivalence testing.
2. Takeda Pharmaceuticals (Japan/USA)
Product Features: Markets the drug under the trade name Uloric. The product is primarily targeted at the US market and has strict FDA approval. It features strict dosage control (available in 40 mg and 80 mg capsules and tablets) and a detailed cardiac safety protocol (in accordance with US regulatory requirements).
3. Menarini Group / Berlin-Chemie (Italy / Germany)
Product Features: Manufacturer of the leading European brand Adenuric. The company's products are distinguished by a high degree of substance purification and proven rapid action (reduction in uric acid levels is observed after just two weeks of therapy). Available in standard European protocol dosages of 80 mg and 120 mg. The drug has been extensively studied in patients with mild to moderate renal impairment.
4. Sun Pharmaceutical Industries Ltd. (India)
Manufactures febuxostat under the brand name Febutaz. Its distinguishing feature is its optimal balance of price and quality. The company uses its own highly purified Indian substances certified to GMP standards, making the drug an affordable alternative to European brands without sacrificing therapeutic efficacy.
5. NAO Severnaya Zvezda (Russia)
One of the most affordable analogues on the Russian market. Available in 80 and 120 mg dosages. It uses finely dispersed lactose as an excipient, ensuring a uniform release of febuxostat, but requires caution in individuals with lactase intolerance.
6. State Enterprise "Akademfarm" (Belarus
The company manufactures Febuxostat-NAN (80 mg and 120 mg). A distinctive feature is that it has passed rigorous local comparative dissolution kinetics (CDC) tests, demonstrating bioequivalence to the original drug. The 120 mg tablets are officially registered not only for the treatment of gout but also for the prevention of tumor lysis syndrome during chemotherapy. The active ingredient contained in each tablet is febuxostat – 80 mg or 120 mg.
Other ingredients: microcrystalline cellulose, lactose monohydrate, hydroxypropyl cellulose, sodium croscarmellose, colloidal silicon dioxide anhydrous, magnesium stearate, polyvinyl alcohol, titanium dioxide (E171), macrogol (polyethylene glycol), talc, iron oxide yellow (E172), sunset yellow (E110), and iron oxide black (E172).
You can download information about the gout remedy "Febuxostat-NAN" from the Company's official website here. Advantages and Innovations In-house production. Highly qualified personnel. Stage of development Already on the market Funding source State budged
Internal
IPR status Exclusive rights
Secret know-how
Sector group BioChemTech
Healthcare
Materials
Client information Type R&D institution Year established 2009 NACE keywords C.21.20 - Manufacture of pharmaceutical preparations
M.72.11 - Research and experimental development on biotechnology
M.74.90 - Other professional, scientific and technical activities n.e.c.
Q.86.90 - Other human health activities
Turnover (in EUR) 10-20M Already engaged in transnational cooperation Yes Additional comments The Republican production unitary enterprise "ACADEMPHARM" is a dynamically developing, science-intensive state-owned pharmaceutical company. Despite its young age in the pharmaceutical industry, "ACADEMPHARM" has already carved out a niche in the domestic market and continues to expand. The company focuses on unmet medical needs, expanding its product range annually.
Activities:
- Laboratory pharmaceutical research;
- Industrial production of medicinal products and other pharmaceuticals, vitamins, vitamin-mineral and metabolic complexes, and nutraceuticals;
- Contract pharmaceutical manufacturing.
Production lines are equipped with the latest equipment from leading global companies, meeting all GMP requirements.
The pharmaceutical quality system includes good manufacturing practices, quality control, and quality risk management. It is fully documented, and its effectiveness is monitored. All components of the quality system are staffed with competent personnel, sufficient facilities, equipment, and technical resources.
Official website of the Enterprise "Academpharm". Certification standards The Republican production unitary enterprise "AKADEMPHARM" holds national GMP (Good Manufacturing Practice) certificates for the production of all forms of its own products.
The company has implemented and operates a pharmaceutical quality system developed in accordance with the requirements of the national standard TKP 030-2017 (33050) "Good Manufacturing Practice" and international requirements. Languages spoken English
Russian
Information about partnership Type of partnership considered Distribution services agreement
Manufacturing agreement
Type and role of partner sought Consumers interested in purchasing "Febuxostat NAN", a medication containing the active ingredient febuxostat and used to treat gout, under a manufacturing agreement.
Partners interested in purchasing "Febuxostat NAN", a medication containing the active ingredient febuxostat and used to treat gout, under a distribution services agreement. Type and size of partner sought > 500
251-500
SME 51-250
SME 11-50
SME <= 10
R&D Institution
University
Sole proprietor

MENAFN28082026008611018181ID1111592824